Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 137, Issue 5, Pages 1001-1011
Publisher
Wiley
Online
2014-05-15
DOI
10.1002/ijc.28976
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TERTPromoter Mutations and Their Association withBRAFV600E Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer
- (2014) Xiaoli Liu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas
- (2014) Miguel Melo et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Lack of Association ofBRAFMutation With Negative Prognostic Indicators in Papillary Thyroid Carcinoma
- (2014) Christopher Gouveia et al. JAMA Otolaryngology-Head & Neck Surgery
- Papillary Microcarcinoma of the Thyroid: Clinical Characteristics and BRAFV600E Mutational Status of 977 Cases
- (2013) Xiangqian Zheng et al. ANNALS OF SURGICAL ONCOLOGY
- Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
- (2013) K. L. Nathanson et al. CLINICAL CANCER RESEARCH
- Postnatal Expression of BRAFV600EDoes Not Induce Thyroid Cancer in Mouse Models of Thyroid Papillary Carcinoma
- (2013) Mika Shimamura et al. ENDOCRINOLOGY
- RAC1b overexpression in papillary thyroid carcinoma: a role to unravel
- (2013) Ana Luísa Silva et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Molecular Testing in Thyroid Cancer
- (2013) Anne R. Cappola et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer
- (2013) Mingzhao Xing et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- DoesBRAFV600E Mutation Predict Aggressive Features in Papillary Thyroid Cancer? Results From Four Endocrine Surgery Centers
- (2013) Carol Li et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Immunohistochemical Detection of Mutated BRAF V600E Supports the Clonal Origin ofBRAF-Induced Thyroid Cancers Along the Spectrum of Disease Progression
- (2013) Ronald A. Ghossein et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Allele Percentage of theBRAFV600E Mutation in Papillary Thyroid Carcinomas and Corresponding Lymph Node Metastases: No Evidence for a Role in Tumor Progression
- (2013) Greta Gandolfi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Targeted Next-Generation Sequencing Panel (ThyroSeq) for Detection of Mutations in Thyroid Cancer
- (2013) Marina N. Nikiforova et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Frequent SomaticTERTPromoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease
- (2013) Iñigo Landa et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
- (2013) Alan L. Ho et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinicopathologic Implications of the BRAFV600E Mutation in Papillary Thyroid Cancer: A Subgroup Analysis of 3130 Cases in a Single Center
- (2013) Jae Yun Lim et al. THYROID
- BRAFV600E Mutation Analysis in Papillary Thyroid Carcinoma: Is it Useful for all Patients?
- (2013) Yasuhiro Ito et al. WORLD JOURNAL OF SURGERY
- Frequency of TERT promoter mutations in human cancers
- (2013) João Vinagre et al. Nature Communications
- Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF -Mutant Thyroid Carcinomas
- (2013) Cristina Montero-Conde et al. Cancer Discovery
- Clinicopathologic and Genetic Characterization of Traditional Serrated Adenomas of the Colon
- (2012) Baojin Fu et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
- (2012) Tomoya Yokota Anti-Cancer Agents in Medicinal Chemistry
- BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer
- (2012) Rachel N. Grisham et al. CANCER
- Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
- (2012) M. Mao et al. CLINICAL CANCER RESEARCH
- In papillary thyroid carcinoma BRAFV600Eis associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval
- (2012) Salvatore Ulisse et al. CLINICAL ENDOCRINOLOGY
- A High Percentage ofBRAFV600EAlleles in Papillary Thyroid Carcinoma Predicts a Poorer Outcome
- (2012) Anna Guerra et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Piece of the Puzzle: What Does BRAF Status Mean in the Management of Patients with Papillary Thyroid Carcinoma?
- (2012) David H. Sarne JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- BRAFV600E Mutation Does Not Mean Distant Metastasis in Thyroid Papillary Carcinomas
- (2012) Valentina Sancisi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- mTOR Pathway Overactivation in BRAF Mutated Papillary Thyroid Carcinoma
- (2012) Alexandra Faustino et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- TheBRAFV600EMutation Is an Independent, Poor Prognostic Factor for the Outcome of Patients with Low-Risk Intrathyroid Papillary Thyroid Carcinoma: Single-Institution Results from a Large Cohort Study
- (2012) Rossella Elisei et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- BRAFV600E mutation and Its Association with Clinicopathological Features of Papillary Thyroid Cancer: A Meta-Analysis
- (2012) Carol Li et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Prediction of Occult Central Lymph Node Metastasis in Papillary Thyroid Carcinoma by PreoperativeBRAFAnalysis Using Fine-Needle Aspiration Biopsy: A Prospective Study
- (2012) Ji-Yong Joo et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Prognostic Implications of miR-146b Expression and Its Functional Role in Papillary Thyroid Carcinoma
- (2012) Chen-Kai Chou et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial Treatment
- (2012) Ralph P. Tufano et al. MEDICINE
- BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype–phenotype correlation
- (2012) Renu K Virk et al. MODERN PATHOLOGY
- Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
- (2012) J. S. Wilmott et al. MOLECULAR CANCER THERAPEUTICS
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Vemurafenib: the first drug approved for BRAF-mutant cancer
- (2012) Gideon Bollag et al. NATURE REVIEWS DRUG DISCOVERY
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma
- (2012) Molly Yancovitz et al. PLoS One
- TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma
- (2012) C. Eloy et al. VIRCHOWS ARCHIV
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody
- (2011) David Capper et al. ACTA NEUROPATHOLOGICA
- The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer
- (2011) Tae Hyuk Kim et al. CANCER
- Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
- (2011) N. Jin et al. CLINICAL CANCER RESEARCH
- A High-Throughput Proteomic Approach Provides Distinct Signatures for Thyroid Cancer Behavior
- (2011) S. Cheng et al. CLINICAL CANCER RESEARCH
- Impact of Mutational Testing on the Diagnosis and Management of Patients with Cytologically Indeterminate Thyroid Nodules: A Prospective Analysis of 1056 FNA Samples
- (2011) Yuri E. Nikiforov et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Primary Occurrence ofBRAFV600EIs a Rare Clonal Event in Papillary Thyroid Carcinoma
- (2011) Anna Guerra et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation
- (2011) Debyani Chakravarty et al. JOURNAL OF CLINICAL INVESTIGATION
- New driver mutations in non-small-cell lung cancer
- (2011) William Pao et al. LANCET ONCOLOGY
- BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
- (2011) E. R. Cantwell-Dorris et al. MOLECULAR CANCER THERAPEUTICS
- Molecular genetics and diagnosis of thyroid cancer
- (2011) Yuri E. Nikiforov et al. Nature Reviews Endocrinology
- Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice
- (2011) A. T. Franco et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Thyroid Cancer Survival in the United States
- (2010) Louise Davies et al. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
- The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204)
- (2010) Joanna Xing et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
- (2010) S. E. Baldus et al. CLINICAL CANCER RESEARCH
- BRAF in primary and recurrent papillary thyroid cancers: the relationship with 131I and 2-[18F]fluoro-2-deoxy-d-glucose uptake ability
- (2010) Susi Barollo et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- BRAFV600EMutation Analysis in Fine-Needle Aspiration Cytology Specimens for Evaluation of Thyroid Nodule: A Large Series in aBRAFV600E-Prevalent Population
- (2010) Sun Wook Kim et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Are the Clinical and Pathological Features of Differentiated Thyroid Carcinoma Really Changed over the Last 35 Years? Study on 4187 Patients from a Single Italian Institution to Answer this Question
- (2010) Rossella Elisei et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions
- (2010) Daria Handkiewicz-Junak et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
- (2010) E. W. Joseph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- B-RafV600E and thrombospondin-1 promote thyroid cancer progression
- (2010) C. Nucera et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BRAF Mutation in Papillary Thyroid Carcinoma in a Japanese Population: Its Lack of Correlation with High-Risk Clinicopathological Features and Disease-Free Survival of Patients
- (2009) Yasuhiro ITO et al. ENDOCRINE JOURNAL
- Molecular cytogenetics of cutaneous melanocytic lesions â diagnostic, prognostic and therapeutic aspects
- (2009) Willeke Am M Blokx et al. HISTOPATHOLOGY
- BRAF mutation in solid cell nest hyperplasia associated with papillary thyroid carcinoma. A precursor lesion?
- (2009) José Cameselle-Teijeiro et al. HUMAN PATHOLOGY
- Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors inBRAFMutant Thyroid Carcinoma Cells
- (2009) Paolo Salerno et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- BrafV600E cooperates with Pten loss to induce metastatic melanoma
- (2009) David Dankort et al. NATURE GENETICS
- A Morpho-Molecular Diagnosis of Papillary Thyroid Carcinoma: BRAF V600E Detection as an Important Tool in Preoperative Evaluation of Fine-Needle Aspirates
- (2009) Ivo Marchetti et al. THYROID
- Acquisition ofBRAFgene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma
- (2008) Vítor Trovisco et al. CLINICAL ENDOCRINOLOGY
- BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma
- (2008) Angela M. Costa et al. CLINICAL ENDOCRINOLOGY
- BRAFV600EMutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study
- (2008) Rossella Elisei et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Molecular characteristics in papillary thyroid cancers (PTCs) with no131I uptake
- (2007) Caterina Mian et al. CLINICAL ENDOCRINOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started